Abstract
Adverse drug reactions, or unintended and harmful outcomes related to the administration of a pharmaceutical product, are a major public health concern, particularly for cancer patients. If counted as a separate cause of death, adverse drug reactions would represent the fourth leading cause of death in the United States. Several legal strategies are available to help mitigate their occurrences and to compensate victims for the harm that results from adverse events. Prior to FDA approval of a drug, the limited size and duration of clinical trials often fail to detect adverse drug reactions. However, after FDA approval, pharmacovigilance efforts are bolstered by recent expansions of FDA post-marketing regulatory powers codified in the 2007 Food and Drug Administration Amendments Act, as well as advances in big data analytics that improve adverse signal detection through data mining of large electronic health records. For victims of adverse drug reactions, tort lawsuits filed in the courts help compensate for the harm suffered and may also serve as warnings to manufacturers to improve drug safety to avoid future legal liability. While encouraging developments have occurred, new and existing legal structures to mitigate and compensate for adverse drug reactions must continue to be refined given increasingly complex pharmaceutical agents.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allison M. Reinventing clinical trials. Nat Biotech. 2012;30(1):41–9.
Almenoff JS, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007;82:157–166.
Aspden P, et al. Preventing medication errors. Washington, DC: National Academies Press; 2007.
Bailey S, et al. Prospective data mining of six products in the US FDA adverse event reporting system. Drug Saf. 2010;33(2):139–46.
Behrman RE, et al. Developing the sentinel system—a national resource for evidence development. N Engl J Med. 2011;364(6):498–9.
Bombardier, C. (2000) “Comparison of Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” 340:1520 New England Journal of Medicine.
Breckenridge A, et al. New horizons in pharmaceutical regulation. Nat Rev Drug Discov. 2012;11(7):501–2.
Carpenter D, et al. The complications of controlling agency time discretion: FDA review deadlines and postmarket drug safety. Am J Polit Sci. 2012;56(1):98–114.
Center for Drug Evaluation and Research. U.S. Food and drug administration, statement of Sandra Kweder before the United States Senate Committee on Finance, 108th Congress, Second Session. 2004.
Chandler v. Simpson (2000), 100 Wash.App. 1034.
Ciociola AA, et al. How drugs are developed and approved by the FDA: current process and future directions. Am J Gastroenterol. 2014;109(5):620–3.
Desai CK, et al. An evaluation of knowledge, attitude, and practice of adverse drug reaction reporting among prescribers at a tertiary care hospital. Perspect Clin Res. 2011;2(4):129.
Duijnhoven RG, et al. Number of patients studied prior to approval of new medicines: a database analysis. PLoS Med. 2013;10(3):e1001407.
Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. The Lancet. 2000;356(9237):1255–9.
El Emam K, et al. A secure distributed logistic regression protocol for the detection of rare adverse drug events. J Am Med Inform Assoc. 2013;20(3):453–61.
Faich G, Morris J. Adverse reaction signaling and disproportionality analysis: an update. Drug Inf J. 2012;46(6):708–714.
FDA. FDA Adverse Event Reporting System (FAERS) statistics. Retrieved 7 June 2016 from http://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070093.htm (2014).
FDA Letter 1. Letter from Joyce Korvick to Alaven Pharmaceuticals. Retrieved 8 June 2016 from http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2009/017854s052_021793s005ltr.pdf (2009).
Fine LA. Drug safety surveillance: Pharmacovigilance in FDA/CDER. Retrieved 8 June 2016 from http://www.fda.gov/downloads/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacultyPrograms/PharmacyStudentExperientialProgramCDER/UCM340626.pdf. (2013).
Food and Drug Administration Amendments Act of 2007, 21 U.S.C. § 355 et seq.
Food and Drug Administration. Risk Evaluation and Mitigation Strategies (REMS). Retrieved 28 Nov 2018 from https://www.fda.gov/Drugs/DrugSafety/REMS/default.htm. (2010)
Gagne JJ, et al. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology (Cambridge, Mass.). 2012;23(2):238.
Government Accountability Office. Drug safety: improvement needed in FDA’s postmarket decision-making and oversight process. GAO-06-402. Washington, DC: GAO; 2006.
Greenfieldboyce N. Big data peeps at your medical records to find drug problems. Retrieved 8 June 2016 from http://www.npr.org/sections/health-shots/2014/07/21/332290342/big-data-peeps-at-your-medical-records-to-find-drug-problems (2014).
Hakala A, et al. Accessibility of trial reports for drugs stalling in development: a systematic assessment of registered trials (2015).
Harpaz R, et al. Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics. 2010;11(Suppl 9):S7.
Harpaz R, et al. Novel data-mining methodologies for adverse drug event discovery and analysis. Clin Pharmacol Ther. 2012;91(6):1010–21.
Harpaz R, et al. Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. J Am Med Inform Assoc. 2013;20:413–9.
Harpaz R, et al. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013;93(6):539–46.
Hochberg A, Hauben M. Time-to-signal comparison for drug safety data-mining algorithms vs. traditional signaling criteria. Clin. Pharmacol Ther. 2009;85(6):600–606.
Hutt P, Merrill R, Grossman L. Food and drug law (2007).
In Re Vioxx Litigation, 395 N.J. Super. 358, 928 A.2d 935 (2007)
Iyer SV, et al. Learning signals of adverse drug-drug interactions from the Unstructured Text of Electronic Health Records. AMIA Summits on Transl Sci Proc. 2013;2013:83.
Johnson JR, et al. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst. 2011;103(8):636–44.
Kaplan S, Staffa JA, Dal Pan GJ. Duration of therapy with metoclopramide: a prescription claims data study. Pharmacoepidemiol Drug Saf. 2007;16:878–81.
Kesselheim AS, et al. Existing FDA pathways have potential to ensure early access to, and appropriate use of, specialty drugs. Health Aff. 2014;33(10):1770–8.
Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012;172(21):1680–1.
Light DW, Lexchin J. Why do cancer drugs get such an easy ride? BMJ. 2015;350:h2068.
Light DW, et al. Institutional corruption of pharmaceuticals and the myth of safe and effective drugs. J Law Med Ethics. 2013;41(3):590–600.
Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Inf J. 2008;42(5):409–19.
Liu M, et al. Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs. J Am Med Inform Assoc. 2012;19(e1):e28–35.
Liu M, et al. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. J Am Med Inform Assoc. 2013;20(3):420–6.
Lynberg MC, Khoury MJ, Lammer EJ, Walker KO, Cordero JF, Erickson JD. Sensitivity, specificity and positive predictive value of multiple malformations in isotretinoin embryopathy surveillance. Teratology. 1990;42(5):513–9.
Marengoni A, Onder G. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ. 2015;350:h1059.
McGuire S. US Department of Agriculture and US Department of Health and Human Services, Dietary Guidelines for Americans, 2010. Washington, DC: US Government Printing Office, January 2011. Adv Nutr: An Int Rev J. 2011;2(3):293–294.
Mini-Sentinel. About mini-sentinel: background. Retrieved 8 June 2015 from http://www.mini-sentinel.org/about_us/default.aspx (2014).
Moore TJ, et al., editors. ISMP quarter watch. Horsham, PA: Institute for Safe Medication Practices; 2012.
Moses C, et al. Pharmacovigilance: an active surveillance system to proactively identify risks for adverse events. Popul Health Manag. 2013;16(3):147–9.
O’Reilly, Van Tassel. Food and drug administration. 4th ed; 2014.
Pal SN, et al. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems. Drug Saf. 2013;36(2):75–81.
Pasricha PJ, Pelivanov N. Drug insight: from disturbed motility to disordered movement: a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol. 2006;3(3):138.
Psaty B. Statement before the United States Senate Committee on Finance, 108th Congress, Second Session. 2004.
Phelps v. Wyeth, Inc. 938 F. Supp. 2d 1055 (2013).
Poluzzi E, et al. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18(6):512–8.
Robb MA, et al. The US food and drug administration’s sentinel initiative: expanding the horizons of medical product safety. Pharmacoepidemiol Drug Saf. 2012;21(S1):9–11.
Rosenstern v. Allergan. 987 F. Supp. 2d 795 (2013).
Schuemie MJ. Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf. 2011;20(3):292–9.
Schuemie MJ, et al. Using electronic health care records for drug safety signal detection: a comparative evaluation of statistical methods. Med Care. 2012;50(10):890–7.
Sherman RE, et al. Expediting drug development—the FDA’s new “Breakthrough Therapy” designation. N Engl J Med. 2013;369(20):1877–80.
Star K, et al. Longitudinal medical records as a complement to routine drug safety signal analysis. Pharmacoepidemiol Drug Saf. 2015;24(5):486–94.
Stephenson C. Yaz, Yasmin may cost Bayer $1.2 billion. Lawyers Weekly USA. 2012.
Strandell J, et al. The development and evaluation of triage algorithms for early discovery of adverse drug interactions. Drug Saf. 2013;36(5):371–88.
Tomlin A, et al. Methods for retrospective detection of drug safety signals and adverse events in electronic general practice records. Drug Saf. 2012;35(9):733–43.
Trifirò G, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275(6):551–61.
Vioxx Litigation. In re: Vioxx products liability litigation, 501 F. Supp. 2d 776 (E.D. La. 2007).
Wahab IA, et al. Comparing time to adverse drug reaction signals in a spontaneous reporting database and a claims database: a case study of rofecoxib-induced myocardial infarction and rosiglitazone-induced heart failure signals in Australia. Drug Saf. 2014;37(1):53–64.
Wang H-W, et al. An experimental investigation of masking in the US FDA adverse event reporting system database. Drug Saf. 2010;33(12):1117–33.
WHO. International drug monitoring: the role of national centres. Tech Rep Serv WHO. 1972;492.
Yoon D, et al. Detection of adverse drug reaction signals using an electronic health records database: comparison of the laboratory extreme abnormality ratio (CLEAR) algorithm. Clin Pharmacol Ther. 2012;91(3):467–74.
Zorych I, et al. Disproportionality methods for pharmacovigilance in longitudinal observational databases. Stat Methods Med Res. 2013;22(1):39–56.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Chen, B., Restaino, J., Tippett, E. (2019). Key Elements in Adverse Drug Reactions Safety Signals: Application of Legal Strategies. In: McKoy, J., West, D. (eds) Cancer Policy: Pharmaceutical Safety. Cancer Treatment and Research, vol 171. Springer, Cham. https://doi.org/10.1007/978-3-319-43896-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-43896-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-43894-8
Online ISBN: 978-3-319-43896-2
eBook Packages: MedicineMedicine (R0)